About: Androgen sensitivity gateway to COVID‐19 disease severity

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Androgen sensitivity gateway to COVID‐19 disease severity Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Androgen sensitivity gateway to COVID‐19 disease severity
Creator	Wambier, Carlos Goren, Andy Mccoy, John Vaño-Galván, Sergio Herrera, Sabina Ossimetha, Angelina Carlos, Correspondence Nau, \| Paulo, \| Ramos, Müller Wambier, Gustavo
source	Medline; PMC
abstract	In this communication, we present arguments for androgen sensitivity as a likely determinant of COVID‐19 disease severity. The androgen sensitivity model explains why males are more likely to develop severe symptoms while children are ostensibly resistant to infection. Further, the model explains the difference in COVID‐19 mortality rates among different ethnicities. Androgen sensitivity is determined by genetic variants of the androgen receptor. The androgen receptor regulates transcription of the transmembrane protease, serine 2 (TMPRSS2), which is required for SARS‐CoV‐2 infectivity. TMPRSS2 primes the Spike protein of the virus, which has two consequences: diminishing viral recognition by neutralizing antibodies and activating SARS‐CoV‐2 for virus‐cell fusion. Genetic variants that have been associated with androgenetic alopecia, prostate cancer, benign prostatic hyperplasia and polycystic ovary syndrome could be associated with host susceptibility. In addition to theoretical epidemiological and molecular mechanisms, there are reports of high rates of androgenetic alopecia of from hospitalized COVID‐19 patients due to severe symptoms. Androgen sensitivity is a likely determinant of COVID‐19 disease severity. We believe that the evidence presented in this communication warrants the initiation of trials using anti‐androgen agents.
has issue date	2020-05-15(xsd:dateTime)
bibo:doi	10.1002/ddr.21688
bibo:pmid	32412125
has license	no-cc
sha1sum (hex)	2525938818cc9b4f76df8595bfc9ff230ea5d995
schema:url	https://doi.org/10.1002/ddr.21688
resource representing a document's title	Androgen sensitivity gateway to COVID‐19 disease severity
has PubMed Central identifier	PMC7273095
has PubMed identifier	32412125
schema:publication	Drug Dev Res
resource representing a document's body	covid:2525938818cc9b4f76df8595bfc9ff230ea5d995#body_text
is schema:about of	named entity 'infectivity' named entity 'regulates transcription' named entity 'determinant' named entity 'sensitivity' named entity 'MECHANISMS' named entity 'alopecia' named entity 'SARS-CoV-2' named entity 'COVID-19' named entity 'model' named entity 'presented' named entity 'prostate cancer' named entity 'Genetic' named entity 'benign prostatic hyperplasia' named entity 'SARS-CoV-2' named entity 'TMPRSS2' named entity 'prostate cancer' named entity 'androgen receptor' named entity 'molecular mechanisms' named entity 'benign prostatic hyperplasia' named entity 'epidemiological' named entity 'anti-androgen' named entity 'Androgen' named entity 'androgens' named entity 'Steroidogenesis' named entity 'gene' named entity 'upper airway infection' named entity 'odds ratio' named entity 'androgenic' named entity 'androgen' named entity 'CAH' named entity 'COVID-19 disease' named entity 'gene polymorphism' named entity 'African American' named entity 'testosterone levels' named entity 'Dr Li Wenliang' named entity 'clinical trials' named entity 'prepubescent children' named entity '36 children' named entity 'polymorphisms' named entity 'lungs' named entity 'Androgen' named entity 'type II pneumocytes' named entity 'androgens' named entity 'TMPRSS2' named entity 'rhinitis' named entity 'gender bias' named entity 'Androgenetic alopecia' named entity 'testosterone' named entity 'androgen' named entity 'direct relationship' named entity 'Epidemiological' named entity 'anti-androgens' named entity 'gene' named entity 'human disease' named entity 'SARS-CoV-2' named entity 'COVID-19' named entity 'chronic obstructive pulmonary disease' named entity 'proteases' named entity 'androgenic' named entity 'lungs' named entity 'colon' named entity 'fetal' named entity 'obesity' named entity 'epidemiologic' named entity 'TMPRSS2' named entity 'COVID-19 disease' named entity 'epidemiological data' named entity 'lungs' named entity 'androgen' named entity '95% CI' named entity 'androgen'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software